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TDITORIAL COMMENT
Novel Technique to Assess
low-Mediated Vasodilation*
hafie Fazel, MD,
ichard D. Weisel, MD, FACC,
ubodh Verma, MD, PHD
oronto, Canada
n this issue of the Journal, Dupuis et al. (1) report on a
ovel technique of assessing flow-mediated vasodilation
FMD) in the brachial artery by scintigraphic hyperemic
eactivity (SHR). This technique, which has the potential to
e integrated into the resting myocardial perfusion scan,
llows noninvasive measurements of endothelial function of
he peripheral vasculature.
See page 1473
The hyperemia induced by re-establishing flow in the
rachial artery after temporary occlusion increases luminal
hear, resulting in the opening of calcium-activated potas-
ium channels and hyperpolarization of the endothelial cells
2). The augmented electric gradient drives calcium entry
nto the endothelial cell that results in endothelial nitric
xide synthase (eNOS) activation and nitric oxide (NO)
laboration, causing vasodilation (3–8). Endothelial denu-
ation or treatment with a NO synthase inhibitor abolishes
MD. However, blood vessels from mice that lack the
NOS gene still respond to shear stress by dilating, most
ikely by a prostanoid-dependent pathway (9). Although
euronal regulation of vasomotor tone also has been impli-
ated in FMD, cardiovascular investigators have focused on
MD as an indirect measurement of endothelial function.
The rationale for gauging endothelial function is to gauge
he propensity of the vasculature to undergo atherosclerosis.
10). The new paradigm of atherosclerosis links oxidative
tress, inflammation, thrombosis, and endothelial dysfunc-
ion (11,12). Endothelium may be a target that integrates
amaging effects of traditional and unknown risk factors
nd may function as a “barometer” that gauges the magni-
ude of atherosclerotic forces (13). For instance, known risk
actors of atherosclerosis have been associated with endo-
helial dysfunction, and endothelial dysfunction appears to
ecome manifest before overt atherosclerosis (14,15).
Risk factor stratification is routine in the practice of the
ardiovascular physician (16) and forms an important cor-
erstone of the “Get with the Guidelines” initiative of the
merican Heart Association. It is clear that aggressive
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Division of Cardiac Surgery, Toronto General Hospital, Toronto,aanada.harmacologic treatment benefits patients who are in the
igh-risk category. However, the treatment of choice and
he extent of treatment are unclear in patients who have
ntermediate risk. According to the National Health And
xamination Survey (NHANES) III data, 40% to 50% of
dults fall into the intermediate-risk group. Further risk
tratification with the use of endothelial function assessment
ould potentially benefit the patients within this large group
ho have a wide range of risk. Indeed, several trials have
xamined the utility of vasomotor functions as a prognos-
icating tool for coronary artery disease (CAD) with modest
uccess (17–25). Albeit not investigated, monitoring endo-
helial dysfunction may provide another readout to which
ardiovascular therapies also may be titrated, as has been
uggested for C-reactive protein (CRP) (26).
Although coronary endothelial function, and not neces-
arily peripheral endothelial function, is the most appropri-
te point of evaluation, the difficulty in noninvasively
onitoring coronary endothelial function prohibits its rou-
ine use. Whether endothelial function in the forearm
eflects coronary endothelial function is debated. On the
ne hand, investigators argue that endothelial dysfunction is
idespread. Risk factors for coronary atherosclerosis are
ystemic risk factors and should affect all vascular trees. For
nstance, the new biomarker of atherosclerosis, systemic
RP (27,28), also partakes in lesion formation by a variety
f mechanisms. C-reactive protein leads to endothelial
ysfunction by destabilizing eNOS messenger ribonucleic
cid and decreasing NO production (29–32). Because these
xperiments were performed on endothelial cells isolated
rom human saphenous veins, it also is very likely that CRP
xerts similar effects on other endothelial cells both in the
eripheral as well as in the coronary circulation. Such
vidence is consistent with the assertion that endothelial
unction in the forearm may relay information about the
therosclerotic propensity within the coronary vasculature.
On the other hand, even in patients with extensive
therosclerosis within the coronary circulation, arteries in
he arm frequently appear to be free of atherosclerosis. In
act, the latter observation has lead some surgeons to adopt
he radial artery as the bypass conduit of choice after the
nternal mammary arteries (33–36). Furthermore, the en-
othelial function of the brachial artery does not always
orrelate with endothelial function of the coronary circula-
ion (37). Thus, the brachial artery reactivity may not always
e directly correlated with coronary endothelial function.
Because of the technical challenges of ultrasonographic
rachial artery evaluation (38) and the invasiveness of
train-gauge venous impedance plethysmography (39,40),
ther methods to measure endothelial function in the
rachial artery would be a welcome addition. The report by
upuis et al. (1) presents a noninvasive alternative that may
e incorporated into the resting myocardial perfusion scan.
here are several issues to discuss concerning the Dupuis etl. (1) report. First, the new technique of SHR has not been
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October 6, 2004:1478–80 Editorial Commentompared with other more accepted methods of FMD
easurement such as by ultrasonography. For validation of
he proposed new test, direct comparison with a gold
tandard is helpful. Second, the intrapatient variability of
HR is not reported. The precision of a new biomarker
ust be evaluated to provide the readers with confidence in
he proposed new test. Third, the authors reported a
ensitivity of 0.7 and specificity of 0.6 in discriminating
etween patients with CAD versus those without CAD.
he modest discriminatory attribute of the test suggests
ignificant limitations in applying the test for further risk
tratification. Fourth, the authors compared patients with
AD who were taking multiple medications to patients
ithout CAD. It is well known that several cardiovascular
rugs, such as the statins, improve endothelial function
41–43). Thus, the authors may have diminished the
iscriminatory power of their study. Last, the other arm of
ach patient served as control. Considering that vasodilators
ere used exclusively in all patients with CAD, the resultant
MD may have been minimal in comparison with the
ontrol arm because of supranormal vasodilation at baseline
aused by drugs. These considerations notwithstanding, the
ase with which SHR may be incorporated into clinical
ractice and clinical trials may significantly add to our
isk-stratification capability and post-diagnosis monitoring
f patients with CAD.
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